Literature DB >> 27919575

A prospective algorithm to reduce anastomotic leaks after rectosigmoid resection for gynecologic malignancies.

E Kalogera1, C C Nitschmann1, S C Dowdy1, W A Cliby1, C L Langstraat2.   

Abstract

OBJECTIVE: Determine whether a standardized protocol for temporary bowel diversion after rectosigmoid resection (RSR) for cytoreduction can reduce the rate of anastomotic leak (AL).
METHODS: A prospective quality improvement project for patients undergoing RSR during debulking surgery from 07/2013 to 01/2016 was conducted. Patients with any of the following underwent temporary diversion: preoperative albumin ≤3.0g/dL, prior pelvic radiation, RSR plus additional large bowel resection (LBR), anastomosis (AS) ≤6cm from the anal verge, failed leak test or contamination of the pelvis with stool. The AL rate was compared to the historic AL rate from 01/04-06/11.
RESULTS: Seventy-seven patients underwent RSR, with 27 (35.1%) receiving diverting stomas vs. 25/309 (8.1%) in the historic cohort. Additional LBR (33.3%) and AS at ≤6cm from anal verge (26.3%) were the most common indications for diversion. No AL was observed among diverted patients. If one AL which occurred following protocol violation (failed leak test but not diverted) is excluded, the theoretical AL rate is 1.3% (1/77) vs. 7.8% (24/309; P=0.039) in the historic cohort. Not excluding this case, the AL rate was 2.6% (2/77) vs. 7.8% (P=0.11). Short-term outcomes following primary surgery were not different between diverted and non-diverted patients. Stoma-related complications were observed in 7/27 (25.9%) patients, primarily related to dehydration. Reversal surgery was successfully performed in 24/75 (88.9%) patients.
CONCLUSIONS: Criteria-based temporary bowel diversion for patients undergoing RSR for gynecologic cancer reduced the AL rate. Diversion was associated with acceptable morbidity and high reversal rate.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anastomotic leak; Large bowel resection; Ovarian cancer; Protective stoma; Rectosigmoid resection

Mesh:

Year:  2016        PMID: 27919575     DOI: 10.1016/j.ygyno.2016.11.032

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  Outcomes after rectosigmoid resection for endometriosis: a systematic literature review.

Authors:  Andrea Balla; Silvia Quaresima; José D Subiela; Mostafa Shalaby; Giuseppe Petrella; Pierpaolo Sileri
Journal:  Int J Colorectal Dis       Date:  2018-05-10       Impact factor: 2.571

2.  Ostomy Does Not Lead to Worse Outcomes After Bowel Resection With Ovarian Cancer: A Systematic Review.

Authors:  Xinlin He; Zhengyu Li
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

3.  Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy.

Authors:  Sumer K Wallace; Jessica W Halverson; Christopher J Jankowski; Stephanie R DeJong; Amy L Weaver; Megan R Weinhold; Bijan J Borah; James P Moriarty; William A Cliby; Daryl J Kor; Andrew A Higgins; Hilary A Otto; Sean C Dowdy; Jamie N Bakkum-Gamez
Journal:  Obstet Gynecol       Date:  2018-05       Impact factor: 7.661

4.  Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience.

Authors:  Barbara Costantini; Virginia Vargiu; Francesco Santullo; Andrea Rosati; Matteo Bruno; Valerio Gallotta; Claudio Lodoli; Rossana Moroni; Fabio Pacelli; Giovanni Scambia; Anna Fagotti
Journal:  Ann Surg Oncol       Date:  2022-04-18       Impact factor: 4.339

5.  Protective ostomies in ovarian cancer surgery: a systematic review and meta-analysis.

Authors:  Beatriz Navarro Santana; Esmeralda Garcia Torralba; Jose Verdu Soriano; Maria Laseca; Alicia Martin Martinez
Journal:  J Gynecol Oncol       Date:  2022-03       Impact factor: 4.401

6.  Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.

Authors:  Deepa M Narasimhulu; Aneesa Thannickal; Amanika Kumar; Amy L Weaver; Michaela E McGree; Carrie L Langstraat; William A Cliby
Journal:  Gynecol Oncol       Date:  2020-12-31       Impact factor: 5.482

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.